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Abstract 
Introduction: Parvovirus B19 (B19V), a single-stranded DNA virus in the family Parvoviridae, is a 
human pathogenic virus, characterized by a selective but not exclusive tropism for erythroid 
progenitor cells. Widely diffuse, it is responsible for an ample range of clinical manifestations, 
whose characteristics and outcomes depend on the interplay between the viral properties and the 
physiological and immune status of the infected individuals. The complexity of virus-host 
relationship and the diversity of the clinical course of infection pose a diagnostic challenge that 
may require non trivial solutions. 
Areas covered: The review includes an updated description of the course of B19V infection in its 
complexity and diversity of pathogenetic mechanisms, discusses the consequent requirements for 
different and appropriated diagnostic approaches, presents the main diagnostic techniques, more 
recent technical advancements, and their application to the diverse clinical situations. 
Expert commentary: The complex scenario of the infectious process and the diversity in possible 
pathogenetic mechanisms make necessary a multi-parametric approach for an accurate and 
informative laboratory diagnosis of B19V infection, combining as much as possible the molecular 
detection of viral components, mainly viral DNA, to commonly followed immunological detection of 
virus-specific antibodies and a critical assessment of laboratory findings. 
Keywords 
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1. Introduction
1.1. Taxonomy 
The family Parvoviridae includes viruses with a single-stranded DNA genome, encapsidated in a 
icosahedral protein capsid, about 22-26 nm in diameter. Replication occurs in the nucleus of 
infected cells and is highly dependent on cellular environment, so that a productive cycle is usually 
achieved only in actively dividing cells, or in some cases when supported by complementation from 
helper viruses. The subfamily Parvovirinae includes viruses infecting vertebrate hosts, within it the 
most recent taxonomical revision distinguishes eight viral genera, and within each genus individual 
virus species that collect the viral isolates normally recognized in clinical or laboratory settings. In 
the genus Erythroparvovirus, the species Primate erythroparvovirus 1 includes the human 
parvovirus B19 (B19V), and a further subdivision is introduced in three distinct B19V genotypes, 
that differ in their genome sequence by about 10%, while constituting a single serotype and 
showing similar biological properties [1]. 
Viruses adapted to the human host are found in the genera Dependoparvovirus (Adeno-Associated 
Viruses, AAV), Erythroparvovirus (B19V), Bocaparvovirus (HBoV1-4), Tetraparvovirus (PARV4). 
While AAV viruses are considered non-pathogenic and have been exploited as transduction viral 
vectors, the others possess a pathogenic potential that prompts for the development of diagnostic 
molecular testing in a clinical setting. B19V is a widely circulating virus implicated in a complex 
relationship with the host, and can be considered the most relevant human pathogenic virus in the 
family, posing the necessity of diagnostic awareness and appropriateness. The aim of this review 
is to present the more recent contributions to our knowledge on the course of virus infection, on its 
pathogenetic mechanisms, and on the appropriate molecular diagnostic methods. 
1.2. The virus and its biology 
B19V shares structural features with other viruses in the family (for more extended reviews, see 
refs [2, 3]). The genome is a linear ssDNA molecule of 5.6 kb in length, strands of either polarity 
are separately encapsidated at the same frequency and are functionally equivalent. The genome 
organization is composed of a unique internal region, containing all the coding sequences, flanked 
by repeated, inverted terminal regions that serve as origins of replication. The unique internal 
region encodes for three major proteins, the non-structural protein NS in the left side, and the two 
colinear capsid proteins, VP1 and VP2, in the right side, and for additional minor non-structural 
proteins. The capsid, composed of 5-10% VP1 and 90-95% VP2 proteins, forms an icosahedral 
structure in T=1 arrangement, about 25 nm in diameter. VP proteins produced in heterologous 
expression systems can self-assemble into viral-like particles (VLPs) that are structurally 
analogous to native virions and are used in diagnostic immunoassays, as well as for a candidate 
vaccine antigen (Figure 1). 
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B19V shows a selective tropism for erythroid progenitor cells in the bone marrow, due to the 
presence of specific receptors, such as the glycolipid globoside and a specific receptor binding the 
VP1 unique N-terminal domain, and to functional internalization processes [4, 5]. In a permissive 
cellular environment, a coordinated series of macromolecular syntheses occurs [6-8]. From the 
parental single-stranded template, cellular DNA repair synthesis generates a double stranded DNA 
template, then a first phase transcription mainly produces mRNAs coding for the NS protein, 
followed by rolling hairpin replication of the genome and extended second phase transcription, 
mainly producing mRNAs coding for structural VP proteins. Accumulation of VP proteins eventually 
leads to the assembly of capsids, encapsidation of progeny single-stranded genomes and release 
of virions from infected cells. The permissive environment is restricted to cells in the erythroid 
lineage at differentiation stages ranging from CFU-E to erythroblasts [7], and is critically dependent 
on Erythropoietin stimulation and hypoxic conditions [6, 8], through a signaling cascade eventually 
leading to formation of a functional replicative complex involving the viral NS and cellular proteins 
[9]. In productively infected cells, the virus exerts a complex series of effects, including arrest of the 
cell cycle and induction of apoptosis [10], thus causing a temporary block in erythropoiesis that can 
manifest as a transient or persistent erythroid aplasia. The virus can infect other different cellular 
types in diverse tissues, including endothelial, stromal, or synovial cells. However, cellular 
environments other than erythroid progenitor cells are normally non-permissive to viral replication, 
so in these the presence and persistence of the viral genome may not be associated with its 
replication, transcription or protein synthesis. In non-erythroid tissues, although a productive viral 
replication that may contribute directly to pathological processes can be sporadically documented, 
infection is usually abortive and the virus is supposed to exert its pathological potential by indirect 
mechanisms, such as the induction of inflammatory or autoimmune processes (extensively 
reviewed in [11] and critically discussed in [12]). 
2. Course of infection
B19V is widely and worldwide diffuse, and infection can be associated with an ample range of 
pathologies and clinical manifestations, from the asymptomatic or mild to the severe and in some 
cases life-threatening, whose characteristics and outcomes depend on the interplay between the 
viral properties and the physiological and immune status of the infected individuals (for more 
extended reviews, [2, 3]). The complexity of virus-host relationship and the diversity of the clinical 
course of infection pose a diagnostic challenge that may require non-trivial solutions. 
2.1. Transmission 
In most epidemiological settings, considering the presence of specific IgG as the marker of 
occurred infection, the highest force of infection occurs before age of 20, reaching a prevalence of 
about 60% in the population aged 20-30 years. Infection can occur until elder ages, reaching 
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maximal prevalence values higher than 80%, and data fitting epidemiological models indicate the 
best scenarios allowing for waning immunity at an age-specific rate over the maintenance of 
lifelong immunity, assuming that the transmission rates are directly proportional to the contact 
rates. The main route of transmission of the virus is through the respiratory system, estimated 
overall R0 values are ~2.4, and duration of contacts is the main determinant of transmission, so 
that prolonged contacts as in the household and community settings are especially effective in 
transmission. In temperate climate countries, circulation of the virus is higher in the Spring/early 
Summer months, and epidemic cycles are reported to occur. For sophisticated epidemiological 
models and related data, see [13-15]. The virus can be transmitted from mother to fetus posing a 
risk of fetal damage that should prompt for an antenatal assessment of risk of fetal infections and 
diagnostic attention towards the development of intrauterine infections (see [16-18] for recent 
reviews). Finally, due to a viremic phase with high viral load, there is a risk of iatrogenic 
transmission of the virus via blood and blood-derived products, implying blood and blood product 
safety issues (see [19, 20] for recent reviews). 
2.2. Infection - Early Events 
Following contact and a primary viremic phase, normally unsuspected and undetected, the virus 
gains access to the bone marrow and infects erythroid progenitor cells, achieving a productive 
infection and exerting cytotoxic effects [21]. In this phase, upon cytological examination, the bone 
marrow shows erythroid aplasia and the presence of characteristic giant erythroblasts (for sample 
images, [22, 23]). The pathogenic effects on bone marrow are derived from the ability of the virus 
to induce cell-cycle arrest, block of erythroid differentiation, and eventually apoptosis of susceptible 
and infected cells. At this stage, the clinical impact on the host reflects the depression of bone 
marrow activity, linked to the volume and turnover rate of the erythroid compartment, and from the 
ability of immune system to mount an effective specific response. 
In individuals with physiological erythropoiesis and normal immune system, infection is limited in 
extent and temporal frame, and is controlled by the development of a specific neutralizing immune 
response. Levels of hemoglobin decrease only marginally and infection is usually asymptomatic 
from the hematological perspective. Production of antibodies with neutralizing activity (IgM followed 
by IgG) contributes to the progressive clearance of infection with constantly decreasing viral load 
levels. When preexisting alterations in the erythropoiesis process, either due to genetic defects or 
stressed physiological conditions, or defects in the immune response, alter the balance between 
viral replication and cellular turnover, infection can manifest as pure red-cell aplasia (PRCA) and 
anemia [24]. In situations where the number of erythroid progenitors and their replication rate is 
expanded because of a reduced lifespan of erythrocytes, or increased need, infection can lead to 
an acute episode of profound anemia, presenting as classical aplastic crisis. In situations where 
the immune system lacks the capacity to control, neutralize, and clear viral infection, the infection 
may become persistent, depression of erythropoiesis can manifest with chronic anemia of different 
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grades, but otherwise erythropoiesis can be compensated and infection clinically unapparent. In 
rare instances, the virus has been linked to bone marrow necrosis [25], and more in general to a 
wide variety of blood diseases and cytopenias other blood cell lineages than the erythroid [21], by 
mechanism that still require investigation. 
2.3. Infection - Late Events 
Bone marrow supports a productive infection and release of progeny virus into the blood, leading 
to a secondary viremia characterized by high viral load levels (up to 1012 virus/mL) in the acute 
phase, further leading to a systemic distribution of the virus and preluding to possible late clinical 
manifestations of infection. In this respect, the two classical late manifestations of B19V infection 
are erythema infectiosum typical of children, and arthropathies typical of adult patients, this latter 
with a tendency to chronicity, but the virus has been implicated, more or less convincingly, as 
etiological agent in a wide range of pathological processes. In particular, in recent years, B19V has 
been recognized as a main cardiotropic virus, and its implication in the development of acute or 
chronic myocardiopathies has been the subject of intense debate (recently summarized in [26]). 
Also, the involvement of B19V in the development of autoimmune disorders has been the subject 
of intense investigation [27], and possible pathogenetic mechanisms involving the formation of 
apoptotic bodies induced by NS protein expression have been proposed [28]. 
In most cases, late clinical manifestations occur in the presence of a specific immune response, so 
that immune-mediated inflammatory processes are assumed. However, it is in this phase that 
different non-erythroid cell types, including endothelial, stromal or synovial cells, can also be 
infected [11, 12]. While these cell types are normally non permissive to viral replication, markers of 
viral activity have in some cases been precisely localized within cells, such as endothelial or 
synovial cells, and causally linked to pathological processes by a direct viral-induced pathogenetic 
mechanism. Over the years, the spectrum of clinical manifestations associated to B19V infection 
has been constantly increasing to involve almost all organs and tissues, and descriptions of clinical 
presentations have progressively stressed atypical aspects. Sound methodologies and strict 
diagnostic criteria should always be adopted to link B19V infection to atypical pathological 
processes. 
2.4. Virus Persistence 
Following primary infection, B19V, or at least B19V DNA, can be detected in peripheral blood for 
prolonged periods, and can then persist in a wide range of tissues, probably lifelong [11, 12], 
raising questions about the actual relevance and pathogenetic implications of these findings. In 
peripheral blood, viremia measured as the detection of viral DNA is considered a marker of active 
infection. However, low levels of viral DNA can be detected for extended period of times following a 
documented past infection [29, 30], and be a rather common finding in the normal population as 
well [31]. Presence of viral DNA in blood has been documented in subjects with congenital or 
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acquired immunodeficiency, in patients receiving chemotherapy for hematological or solid 
malignancies [32, 33] and in the course of immunosuppressive treatments in bone marrow [34, 35] 
or solid organ transplant recipients [36-39]. Presence of viral DNA is interpreted as indicating the 
occurrence of persistent infections, although not necessarily associated with underlying 
pathogenetic mechanisms and with clinically relevant situations. Recently, it has been 
demonstrated that an analytical differentiation can be introduced between the detection of viral 
DNA within virions, thus related to an active productive infection, and circulating free viral DNA, 
possibly released from sites of persistence in the tissues, in a concept similar to that of liquid 
biopsy [40]. The clinically utility of such differentiation has probably just begun to be appreciated 
[41]. 
Concerning persistence in tissues, a comprehensive review of available published information 
indicates that the average overall frequency of samples positive for B19V DNA in all tissues, 
including bone marrow, lymphoid tissues, liver, heart, synovia, skin, testis, thyroid, and brain is as 
high as 44.8% [11]. The virus can be detected in bone marrow, the primary target organ, not only 
in cases of active infections with constant low-level viremia, but also in ~20 % of biopsies from 
subjects without any evidence of active viral replication, and can be detected also in lymphoid 
tissue, including spleen, lymph nodes, and tonsils [11]. Viral DNA can be detected in liver, and in 
the heart the common presence of B19V DNA has raised attention on its potential role in the 
development of cardiomyopathies [42-44]. Viral DNA is commonly found in synovial tissues, thus 
with little informative content when trying to relate its presence to the development of 
rheumatologic diseases [27], and skin, with similar implication with respect to dermatological 
issues [45, 46]. In all these instances, large-scale surveys have demonstrated the persistence of 
viral DNA in substantial fractions of sample populations, independently of clinical associations, so 
its mere detection cannot be assumed as a diagnostic criteria suggestive of a virus-driven 
pathological process. Additional parameters, such as the demonstration of expression of viral 
mRNAs and proteins, need to be assessed to postulate B19V as the pathogenetic agent in 
observed concurrent alterations in host cells and tissues and related clinical manifestations. 
On the whole, the initial idea of a virus capable of acute infections but rapidly cleared from the 
organism has given place to the concept of a virus able to establish long-term relationship with 
human hosts, and the current assumption is that persistence of viral DNA in tissues can be the 
normal outcome of infections, making B19V a relevant part of the human virome in its expanding 
concept [47-49]. Strikingly, viral DNA detected in tissues can provide an archive for ancient 
genomic variants that are not currently circulating, bearing witness to an active evolutionary 
process involving B19V and leading to its actual differentiation in the three recognized genotypes 
[50, 51]. What is observed in the population is a stratification of archived variants in the different 
age groups, from ancient and extinct to recent and circulating variants. Whether this persistence 
might be due to silent maintenance of viral genomes as episomes, to integration of viral DNA in the 
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host genome as recently observed in erythroid cells in vitro [52], or be related to periodical 
reactivation from latent reservoirs leading to productive infections, is still a matter of investigation 
[12]. Until a better understanding of the characteristics of this long-term relationship is obtained, 
and pathogenetic mechanisms are better understood, so the relevance of diagnostic markers will 
continue to be a matter of debate, requiring careful assessment and interpretation for clinical utility. 
2.5. B19V as a cardiotropic virus 
The interpretation of the presence of viral DNA in tissues as a clue to the development of 
pathologies is nowhere such controversial as for its detection in heart tissues. As already stated, in 
recent years, B19V has gained interest as a cardiotropic virus, being detected at ever increasing 
frequencies in endomyocardial biopsies, replacing other cardiotropic viruses as the most prevalent 
virus detected in the heart, and a marked cardiotropism should be mentioned as one of the main 
characteristics of B19V. A recent extensive review summarizes the still partial and contradictory 
findings collected until now on the role of B19V in the development and clinical course of 
myocarditis and chronic dilated cardiomyopathy [26]. 
It is demonstrated that B19V can infect myocardial endothelial cells, thus a proposed (but not 
thoroughly validated) pathogenetic mechanism would involve in sequence a direct cytotoxic and 
proinflammatory activity exerted by viral NS and VP1 proteins on endothelial cells, then followed by 
recruitment and activation of inflammatory and immune cells leading to endothelial disfunction and 
CTL-mediated tissue damage, and finally to persistence of virus in tissues, possibly associated to 
chronic inflammation and cardiomyopathy. Such pathogenetic mechanism would require not only 
infection of endothelial cells, but also viral replication or at least expression of viral proteins, which 
is a testable hypothesis through quantitative determination of viral DNA per number of cells and 
detection of viral mRNAs and proteins in endomyocardial biopsies [26]. 
On these grounds, B19V has been directly involved as an etiologic agent in acute myocarditis both 
in pediatric [53] and adult populations [54]. On the other hand, the reported frequency of detection 
of B19V DNA in endomyocardial biopsies in sample populations, controls as well as patient 
groups, shows a wide variability, is usually higher in recent works that can probably use more 
sensitive detection methods, and as a consequence there is no consensus on the relevance of the 
presence of viral DNA either as a diagnostic or prognostic parameter in the development of 
cardiomyopathies, in particular dilated cardiomyopathy and ventricular dysfunction. A suggestion 
for involvement of B19V in coronary artery disease has also been reported [55]. In fact, a 
significant pathogenetic association has been hypothesized because of significant higher 
frequencies of B19V DNA detection in patient versus control groups, or of the presence of higher 
mean viral loads suggesting active viral replication. However, by using these same indicators, a 
lack of significant clinical association has also been recently advocated [56]. Reasons for these 
discrepancies are not readily evident, and may involve sample population composition, different 
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selection of clinical parameters and evaluation endpoints, inherent variability in tissue sampling 
and differences in the molecular assessment methodologies. Investigation of markers of viral 
activity, such as the presence of viral transcripts or viral proteins, may better identify subset of 
patients where B19V acts a more direct pathogenetic role [57]. The rare occurrence of clinically 
relevant myocarditis and development of cardiomyopathies compared to the widespread diffusion 
of B19V infections underscores the relevance of coincident factors, that are presently ignored. A 
predisposing genetic background, viral coinfections (e.g., with HHV-6), the extent of vascular 
damage [58], the activation of the innate immune system, or the characteristics of the adaptive 
specific anti-B19V immunity, can all contribute critically in the development of B19V-related 
cardiomyopathies. Pertinent in vitro experimental models and standardization of analytical 
procedures will be required in future studies to obtain reliable information on the role of B19V in the 
development of acute or chronic cardiomyopathies. 
2.6. Fetal Infection 
A relevant property of B19V is its ability to cross the placental barrier and infect the fetus [16]. 
When in the fetal circulation, the virus can infect erythroid progenitor cells, in liver and/or bone 
marrow depending on the gestational age, and can be detected in erythroid cells circulating in the 
vessels of several tissues, in endothelial placental cells as well as in the amniotic fluid. The virus 
can induce a block in fetal erythropoiesis whose effect will depend on fetal developmental stage, 
the rate of expansion of fetal erythroid compartment and the maturity of the immune response. 
Infections occurring at earlier stages of pregnancy carry a higher risk of fetal death, up to about 
10%, while infections occurring in the central part of pregnancy more frequently lead to fetal 
hydrops. Hydrops may eventually cause fetal death, but frequently the fetus can recover without 
persistent developmental damage. In the third trimester the overall risk of fetal damage decreases 
to background values, although late intrauterine fetal death can occur [17, 59]. Conservative 
management of documented infections is advised, with an indication for improved survival 
following intrauterine transfusions in case of documented fetal anemia below a threshold level [60]. 
Newborns may show transient presence of virus at birth, only sporadically associated with neonatal 
anemia or anomalies [18]. Parvovirus B19 infection during pregnancy is not associated with 
increased morbidity or mortality in infancy and childhood [61], while consequences of fetal anemia 
on the long-term neurological development are hypothesized, but still under investigation [62]. In 
view of the fact that effective protocols are established for an appropriate management of 
intrauterine infections, it is rather contradictory that antenatal screening and generalized 
surveillance are not recommended [63, 64], although their introduction would prove useful [65, 66]. 
As a consequence, diagnostic algorithms mostly focus on a diagnosis of suspected active infection 
in pregnancy and on confirmation of fetal infection. Usually antibody detection in maternal blood 
are sought as a first-level investigation, but in most instances it will be necessary to include a 
molecular detection of virus in maternal blood as well as on fetal specimens to achieve a definite 
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diagnosis and guide clinical management [67, 68], including recommendation for intrauterine 
transfusion [69]. 
 
3. Molecular detection assays 
3.1. Specimens and Molecular Targets 
The low structural complexity of B19V restricts the range of molecular targets relevant for a direct 
diagnosis of infection mainly to viral DNA. Detection of viral DNA in serum/plasma from peripheral 
blood, other body fluids, fetal cord blood, or amniotic fluid, is an indication of productive viral 
replication and active infection. Due to the characteristics of the viral replication and the dynamics 
of the infectious process, it is critical for diagnostic methods to produce a reliable quantitative 
assessment of the viral load in order to obtain useful diagnostic information. Furthermore, recent 
indication is emerging for the analytical differentiation between the detection of viral DNA within 
virions, and circulating free viral DNA. Viral DNA can also be sought in cellular samples, such as 
bone marrow aspirates, solid tissue biopsies, fetal tissue or placenta. When investigating tissue 
samples, in order to differentiate active infections from silent persistence of virus, both quantitative 
evaluation of the genome copy number and detection of viral mRNAs can be considered 
appropriate. To this purpose, besides quantitative molecular amplification methods, viral nucleic 
acids may be detected by in situ hybridization, or viral proteins can be detected by immunological 
methods. 
3.2. qPCR Techniques 
Over the years, in the progress towards a rapid and accurate molecular diagnosis, a wide array of 
molecular hybridization and nucleic acid amplification techniques have been developed. Currently, 
quantitative and internally controlled real-time PCR techniques (qPCR) represent the standard 
analytical method for the molecular detection of B19V DNA. Two main requirements should be 
met: (i) the capability of detection of all genotypes of B19V, and (ii) a calibrated and standardized 
quantification of target. Both of these take advantage of international standards [70] and can be 
challenged by international proficiency panels. 
B19V Genotypes. B19V as a species is subdivided into three genotypes, the prototype genotype 
1, and two variant genotypes 2 and 3. At the nucleotide level, the diversity between genotype 
clusters is about 10%, while the diversity within each genotype cluster is normally lower than 2% 
for genotype 1 and in the range 3-10% for genotypes 2 and 3 [71]. All genotypes co-circulate, but 
with different frequencies and geographical distributions [72-74]. The prototype genotype 1 is 
ubiquitous worldwide and includes the greatest part of circulating virus, mainly referred to as 
subtype 1a, while a subtype 1b and other minor variants are rarer and confined to limited 
geographical areas. Genotype 2 appears to be the older variant with respect to genotypes 1, can 
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be detected as the most common genotype in ancient tissues and is commonly harbored in tissues 
of elderly populations, while is only sporadically detected as circulating virus. Genotype 3, also an 
old variant divided in the two distinct subtypes 3a and 3b, circulates at relatively higher frequencies 
in western Africa and at lower frequencies in other geographic areas. The three B19V genotypes 
share similar biological properties, pathogenic capacity, transmission routes, and pose a similar 
diagnostic challenge in the clinical setting. Hence, nucleic acid detection procedures should enable 
the detection and standardized quantification of all genotypes. 
The pursuit of these main requirements can take advantage of an ample amount of sequence 
information from nucleotide databases, included that of international standards as reference 
materials for all genotypes [75]. However, the extent of sequence diversity that can be expected in 
the clinical isolates needs to be taken into account. For genotype 1, available sequence 
information indicates a continuous evolutionary process, with a rather high mutation rate coupled to 
contrasting selection pressures on different genomic regions [76], but alignment algorithms still 
yield a consistent consensus sequence coupled with a limited genetic diversity within isolates 
collected over wide temporal and geographical ranges [77]. This low genetic diversity of genotype 
1 suggests that primers and probes designed and used in molecular detection assays will 
recognize most targets with high probability. Genotypes 2 and 3 pose different problems. In both 
cases, fewer genomic sequences are presently available, inter- and intra-genotypic diversity is 
higher, the consistency of consensus sequences is lower than for genotype 1, and it may be 
expected that addition of new sequences may demonstrate additional genetic diversity. This higher 
sequence divergence may pose diagnostic challenges, and primers and probes may recognize 
targets with lower probability. 
Considerations on genotype distribution and sequence heterogeneity among isolates should guide 
the design of primers and probes for a molecular amplification assay [78-80]. Sequence alignment 
permits the definition of consensus sequences for each genotype, and of a whole-species 
consensus that can be used to define positions of amplification primers and probes. However, any 
choice of primers and probes does not exclude the possibility of mismatches to individual clinical 
isolates, causing impaired annealing and leading to underestimation or misdetection of targets. In 
well-designed assays, single base mismatches can be present either on one of the primer binding 
sites, or on the probe binding site, at an expected frequency lower than 1%. Dual targeting assays 
are an alternative to minimize the risk of mismatching and underreporting positive samples [81]. 
Analytical performance. Different qPCR protocols have been developed to allow choice with 
respect to operational systems and diagnostic requirements. Consensus genotype-independent 
detection of B19V DNA by means of intercalating dyes may be an alternative to genotype specific 
detection by means of fluorescence probes, or the two detection formats may be successfully 
combined maintaining equal sensitivity and specificity of the assay. This latter scheme would 
guarantee a specific identification of prototype or variant genotypes coupled to a high flexibility in 
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the detection of newly-emerging variants with possible additional sequence heterogeneity [78]. 
Analytical performance of the designed molecular assay, both in house as well as commercially 
available, should be evaluated according to guidelines for harmonization in analytical assays 
towards the international panel of standard reference material. Analytical requirements need to be 
met in terms of limit of detection and quantification, and linear range of the assay, and results 
reported in International Units (IU) rather than genome copies. Calibration of the assay in IU, as 
defined by WHO standards (1st WHO International Reference Panel for Parvovirus B19 Genotypes 
for NAT based assays NIBSC code: 09/110; and the related 3rd WHO International Standard for 
B19V, NIBSC 12/208), will reduce inter-lab heterogeneity in reporting of results and facilitate 
comparison of data collected in different experimental settings. Concerning assay setup, a useful 
and physically meaningful lower limit of detection or quantification should be set at 95% confidence 
in the range 102-103 IU/mL, while the range of linearity of the assay should extend to at least from 
103 IU/mL up to 109 IU/mL. Diagnostic laboratories can rely on commercially-available validated 
diagnostic assays. However, diagnostic kits encounter problems due to target heterogeneity, and 
for B19V some reports and proficiency panel evaluations suggest that these qPCR assays may not 
always conform to analytical performance standards [82]. Conversely, the in-house development of 
molecular assays may allow a wider operational choice but requires a high degree of conformity to 
analytical guidelines and validation procedures to ensure reliable results. It is worth noting that 
there are relatively few published reports on the analytical validation of molecular assays aimed at 
detecting B19V DNA, and mainly in the context of blood safety issues [81, 83]. Information on the 
analytical and clinical performance of molecular diagnostic assays would indeed prove extremely 
useful in the context of diagnostic laboratories. 
3.3. In Situ Hybridization Techniques 
A useful complement to qPCR is offered by in situ hybridization for the detection of viral nucleic 
acids within cells or tissues, with preservation of cellular morphology. In the case of biopsies, the 
quantitative information offered by qPCR on purified nucleic acids should not be considered of 
primary relevance, even if standardized by a reference endogenous target, because of the 
variability inherent in the sampling of a non-uniform cell population with different degrees of 
permissiveness to viral replication or different spread of virus. By in situ hybridization techniques, 
infected cells can be easily identified in the sampled material and give indication on the distribution 
of infection within tissues, and to what cellular types are involved. Several methodologies have 
been developed, differing in the choice of probe (DNA, oligo-DNA, or oligo-PNA probes), labeling 
method and moiety, and detection method. Immunofluorescence or immunoenzymatic detection 
methods can be successfully used. In the latter case, chromogenic substrates offer the advantage 
of an easy microscopic inspection of the analyzed tissue, while the use of chemiluminescent 
substrates may offer the advantage of a quantitative assessment of the abundance of targets 
within infected cells [84], although at the expense of sophisticated equipment. Coupling of 
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fluorescent in situ hybridization techniques to cytofluorimetric cell population analysis is also 
feasible and can yield valuable information on the distribution of infected cells in a complex cell 
population [85], but it is technically demanding and its application in a diagnostic setting will require 
further standardization. 
3.4. Antigen Detection Techniques 
Immunological detection of viral proteins is not advisable for detection of virus in blood, unless for 
low-sensitivity screenings [86], but can be considered as an useful tool for identification of 
productively infected cells in tissue samples and a complement to in situ hybridization techniques. 
Commercially available monoclonal or polyclonal antibodies are directed against the viral capsid 
proteins, mostly towards the VP1/VP2 common epitopes. In selected applications, mainly when 
investigating the presence, expression and role of B19V in atypical contexts, in situ hybridization 
techniques, immunologic detection of viral proteins, and/or of cellular markers, might be combined 
to better characterize a productive viral infection and identify the phenotype of target cells [11]. 
3.5. Antibody detection assays 
Detection of a specific immune response by the presence of anti-B19V antibodies specific to B19V 
capsid antigens is still now considered the standard and most widely used means of laboratory 
diagnosis of B19V infection. Indirect markers of active viral infection have recently been identified, 
such as the production of chemokine CXCL10 [87], or high neopterin levels indicative of a cell-
mediated immune response [30], however parallel detection of specific anti-B19 IgM and IgG 
antibodies is required and interpretation of the combination of results may allow for a presumptive 
diagnosis of active, recent or past infection [88]. VP antigens used for immunological detection are 
obtained by means of heterologous recombinant expression systems and, depending on their 
characteristics and assay setup, can offer different information useful for interpretation of a specific 
immune response [79, 89]. Recombinant proteins expressed in prokaryotic systems lose their 
native conformation and are suitable for the detection of immunity against linear epitopes, while 
recombinant proteins expressed in eukaryotic system can maintain native conformation and can be 
used to detect immunity against conformational epitopes [90-92]. In particular, viral capsid proteins 
assemble as VLPs with antigenic configuration quite similar to that on native virus and are the 
recognized standard for immunological detection. Commercially available enzyme immunoassays, 
or chemiluminescent immunoassays, can use VLPs composed of VP2 only, or VP2+VP1, or 
VP2+VP1 expressed in prokaryotic systems, to allow detection of antibodies to conformational VP2 
or also VP1 linear epitopes. Available Line blot assays include an array of conformational and 
linear antigens, and can be used as a confirmatory assay to dissect the range of antibody 
response to B19V. Of limited availability and not widely used, although potentially useful to 
determine the timing with respect to onset of infection, are assays to determine IgG avidity [93], or 
acute-phase, epitope specific reactivity [94]. Recent technical developments aimed at the setup of 
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homogenous phase, multiplexed assays, first proposed the use of array-in-well IgG antibody 
detection, coupled to photon emitting nanoparticles and photoluminescence reporter technology 
[95], then a Luminex-based assay for the detection of specific IgG, potentially combined in a 
multiplex assay aimed at antenatal screening [96]. 
Given the scarcity of comparative evaluation of tests as reported in the recent literature [79, 97], 
the operative choice within currently available test formats and platforms is open to different and 
somewhat subjective evaluations, and comparison of results obtained with different assays is 
uncertain. The analytical interpretation of test results is suggested by the manufacturers, but also 
considering the possibility of falsely reactive results frequently due to heterologous polyclonal 
activation or antigenic cross reactivity, the clinical interpretation of analytical results requires a 
more cautious and independent approach to identify a meaningful clinical cut-off. 
3.6. Future developments 
Apart from qPCR, other molecular amplification techniques and detection formats have not 
maintained a reliable utility in the diagnostic laboratories, and have not been reported in the 
scientific literature in the context of an extended clinical use. However, some technical 
improvements can still be pursued, in a double direction. First, towards the development of 
dedicated point-of care, lab-on-chip devices, able to couple amplification and detection of 
molecular targets on stand-alone equipment [98, 99]. Then, towards the inclusion of B19V as 
target in innovative array-based assays, that can couple amplification and detection in a format 
enabling identification of its presence within an ample set of possible infectious agents [100-104]. 
Implementation of such assays in the current diagnostic algorithms remains at present a 
stimulating challenge. 
Next generation sequencing methodologies are increasingly applied to investigation of clinical 
samples, and metagenomic investigations can be aimed at the identification of viral sequences in 
either blood or solid tissues. B19V genomic sequences have been detected in blood as part of the 
plasma virome in normal population [31], in peculiar epidemiological and clinical contexts [105], or 
in situations with underlying pathological process in the quest for etiological infectious agents [106-
108]. This kind of experimental evidence is only now becoming to accumulate and will likely 
provide valuable information on the presence and relevance of B19V in many pathological 
processes. Presently, independently of the technique employed, it is useful to remind that the mere 
presence of viral genomic sequences, or even viral messengers, is by itself insufficient to claim for 
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B19V is a possible etiological agent in a large ensemble of diseases, with a main target on 
erythroid progenitor cells in bone marrow but encompassing practically all tissues and organs, 
intrauterine infections included. An extended awareness and definition of the actual pathogenic 
role of B19V among human diseases will be fostered by the development of better diagnostic 
methods and algorithms. In this respect, integration of the common immunological diagnostic 
scheme with the application of molecular detection methods will be crucial. Molecular detection of 
B19V is easy and reliable. qPCR techniques for the detection of B19V can be carried out from 
biological specimens with standard pre-analytical processing procedures. The choice of qPCR 
techniques range from commercially-available, to integrated in common-flow analytical platforms, 
to the tailored or lab-developed assays, requiring standard laboratory equipment. Development of 
even more versatile analytical platforms, of alternative molecular assays with point-of-care 
characteristics, will widen in the future the opportunities for molecular testing for B19V, aimed at 
improving performance and informative content, and reducing time and costs. The pattern of B19V 
genetic evolution and diversity, its biological characteristics and complex relationship with the host, 
its diverse clinical manifestations of infection, are all topics that are far from completely understood, 
and will benefit from information emerging from the wider use of molecular diagnostic approaches 
and development of innovative methodologies. 
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Expert commentary 
Given the complex scenario of the infectious process and the diversity in possible pathogenetic 
mechanisms, an accurate and informative laboratory diagnosis of B19V infection necessarily relies 
on a multi-parametric approach, combining as much as possible the molecular detection of viral 
components, mainly viral DNA, to the immunological detection of virus-specific antibodies. A 
laboratory diagnosis is necessary to confirm or exclude B19V infection, to differentiate acute from 
persistent infections, and in the follow-up of documented infections. Investigation to document a 
B19V infection can be rather straightforward, or be part of complex diagnostic workouts in atypical 
clinical settings. Moreover, B19V detection can be part of screening procedures, especially 
considering antenatal screening, or part of prophylactic measures to prevent iatrogenic 
transmission of virus. All of these diagnostic needs will take advantage of an integrated molecular 
and immunological approach and require a critical assessment of laboratory findings. In Figure 2, 
the analytical profile obtained in a set of serum samples by parallel detection of anti-B19V IgM and 
IgG antibodies, and of viral DNA by qPCR, is reported, highlighting the complex picture that can be 
obtained when investigating for a B19V infection and the consequent necessity of integration of 
molecular and immunological data for a correct and timely diagnosis. 
Practically, the indirect, immunological approach to the diagnosis of B19V infection is commonly 
followed as a first level investigation. The acute phase of infection is characterized by high viremic 
load and the emergence of specific IgM/IgG antibodies and is normally followed by a progressive 
clearance of viremia still in the presence of specific IgM and IgG, or may lead to persistent 
infections, usually in the presence of IgG only, and finally may result in the silent persistence of 
virus in tissues. Thus, coupled determination of IgG/IgM antibodies against VP proteins is required. 
The presence of IgM reactivity is indicative of an active or recent infection, and a repeated 
determination can be used as a confirmatory assay. In addition, assays able to discriminate a 
differential reactivity of IgG against conformational or linear epitopes can be used to confirm or 
better characterize the immunological response. However, the immunological approach presents 
intrinsic limitations that prompt molecular diagnostic testing. 
Indications for molecular testing include the confirmation of suspected active infections, the follow-
up of the course of documented infections, and the characterization of persistent infections. 
Molecular analysis is normally carried out from peripheral blood since productive infections are 
characterized by viremia, and viremic levels are correlated with the clinical course. Both serum and 
plasma are suitable samples, so that detection of both viral genomes and specific antibodies can 
be obtained from the same sample. The highest viremic levels are reached in the initial phase of 
infection, before or coupled to the development of a detectable immune response. In this case, a 
single immunological determination may yield unreliable results, while repeated testing will lead to 
a delay in diagnosis. In a later phase of infection, progressively lowering viral loads can be 
The clinical use of Parvovirus Assays, p.17 
detected in the presence of both IgG and IgM. Clearance of viremia might be delayed and parallel 
the waning of IgM, but in persistent infections even sustained levels of viremia can be present 
when IgM are no longer detected. In immunodeficient, immunosuppressed, or in transfused (and 
IVIG-treated) patients, antibody detection is just unreliable for diagnostic purposes and detection of 
viral DNA should be considered the only relevant diagnostic parameter. In antenatal screening or 
prenatal diagnosis, relying on maternal immune status only will lead to underestimation of active 
infections in the mother and correlated risk to fetus, so detection of viral DNA in maternal blood 
should be part of the diagnostic workup. 
In addition to determination of the immune status of infected individuals, molecular amplification 
methods leading to a reliable quantitative assessment of viral load in an ample dynamic range are 
critically required to obtain useful diagnostic information. In fact, considering peripheral blood as 
the sample of choice and the characteristics of a typical time course of infection, a high viral load in 
the acute phase will progressively decline to lower levels in the following months, but even in 
normal subjects a complete clearance of B19V DNA from peripheral blood may not be achieved in 
a short time. Therefore, the diagnostic question will be to discriminate this normal situation from an 
active, persistent infection and determination of the viral load in the course of time is the only 
relevant parameter for this purpose, with the recently realized caveat that target viral DNA may be 
in the form of free DNA and not directly correlated to a persistent productive infection. In pregnant 
women, either in case of antenatal screening or in response to a specific diagnostic question, 
determination of B19V DNA is a more reliable marker of infection than determination of the 
immunological status, while confirmation of intrauterine or congenital infection necessarily relies on 
the detection of B19V DNA in fetal or neonatal samples. It is important that all viral genotypes are 
detected by a molecular assay with the same analytical sensitivity, although genotyping can be a 
secondary issue with respect to diagnosis. Sequencing of amplification products might be carried 
mainly for epidemiological studies, especially to confirm the presence and identity of variant 
genotypes, but its clinical utility still remains questionable until some sound correlation emerges 
between a particular sequence variant and peculiar pathological processes, which has not been 
the case until now. 
In case of predominant hematological involvement the virus can also be detected from bone 
marrow aspirates or biopsies, where molecular detection methods should be performed in addition 
to histologic examination. Biopsy samples can be obtained from other tissues where an active 
B19V infection is suspected, for example in the case of acute myocarditis, and in these instances 
quantitative molecular assays will be useful in the differentiation between an active infection or the 
mere persistence of viral genomes. Molecular analysis are necessary to confirm infection of the 
fetus, and for this purpose it is not necessary to analyze cord blood, since the virus can also be 
detected in amniotic fluid, or in placenta at term, or in biopsies in the case of post-mortem analysis. 
In all these situations, whenever possible, qPCR assays should be usefully complemented by in 
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situ hybridization or antigen detection techniques to yield information not only on the presence of 
virus, but also on its expression and the extent of infection in the different cell types within the 
sampled tissue. 
Five-year view 
B19V is still underestimated from a clinical perspective. Its wide circulation and prevalent benign 
and self-limiting clinical course generally lead to a diminished appreciation of its pathogenic 
potential. However, B19V is a relevant human pathogenic virus, and an effort should be 
undertaken to improve diagnostic awareness and appropriateness. Integration of the common 
immunological diagnostic scheme with the application of molecular detection methods should be 
pursued whenever possible, given that both antibody detection and molecular assays are available 
as commercial tests, in some cases already integrated on analytical platforms. Benchmark analysis 
should be presented to assist in operational choice with respect to different available tests. In the 
future, important information on the role of B19V in the development of pathological process is 
expected from application of NGS techniques directed at analyzing the metagenomic structure and 
expression patterns in diseased tissues, and this may translate in the individuation of relevant 
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Key issues 
• Parvovirus B19 (B19V), a ssDNA in the family Parvoviridae, is a widely circulating human 
pathogenic virus, implicated in a complex relationship with the host and ample range of 
clinical manifestations, posing the necessity of diagnostic awareness and appropriateness. 
• B19V shows a selective tropism for erythroid progenitor cells, productive infection causes a 
temporary block in erythropoiesis that can manifest as a transient or persistent erythroid 
aplasia. The role of the immune system in controlling infection is crucial. 
• In non-erythroid tissues, including endothelial, stromal, or synovial cells, infection is usually 
abortive and the virus is supposed to exert its pathological potential by indirect mechanisms, 
such as the induction of inflammatory or autoimmune processes. 
• The virus can persist in diverse tissues, so the mere detection viral DNA cannot be assumed 
as a diagnostic criteria sufficient for assessment of a direct pathogenetic role. 
• The virus can be transmitted from mother to fetus, posing a risk of fetal damage that should 
prompt for an antenatal assessment of risk of fetal infections and diagnostic attention 
towards the development of intrauterine infections. 
• The range of molecular targets relevant for a direct diagnosis of infection is restricted mainly 
to viral DNA. qPCR is the method of choice, and in the diversity of proposed assays two 
main requirements should be met: (i) the capability of detection of all genotypes of B19V, and 
(ii) a calibrated and standardized quantification of target. 
• qPCR can be useful complemented by in situ hybridization detection methods for the 
detection of viral nucleic acids within cells or tissues, and/or by immunologic detection of viral 
proteins, to better characterize a productive viral infection and identify the phenotype of 
target cells. 
• Detection of a specific immune response by the presence of anti-B19V antibodies is 
considered the standard and most widely used means of laboratory diagnosis of B19V 
infection. Parallel detection of specific anti-B19 IgM and IgG antibodies is required and 
interpretation of the combination of results may allow for a presumptive diagnosis of active, 
recent or past infection. 
• Given the complex scenario of the infectious process and the diversity in possible 
pathogenetic mechanisms, an accurate and informative laboratory diagnosis of B19V 
infection necessarily relies on a multi-parametric approach, combining as much as possible 
the molecular detection of viral components, mainly viral DNA, to the detection of virus-
specific antibodies. 
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Figure Legends 
 
Figure 1. B19V genome organization and virion structure. 
Top: coding sequences for the viral proteins: NS, non-structural protein; VP, structural proteins, 
colinear VP1 and VP2, assembled in a T=1 icosahedral capsid; 7.5 kDa, 9.0 kDa, 11 kDa: minor 
non-structural proteins. 
Center: a schematic diagram of B19V genome indicating the two inverted terminal regions (ITR), 
and the internal region (IR) with the distribution of cis-acting functional sites (P6, promoter; pAp1, 
pAp2, proximal cleavage-polyadenylation sites; pAd, distal cleavage-polyadenylation site; D1, D2, 
splice donor sites; A1.1, A1.2, A2.1, A2.2, splice acceptor sites). 
Bottom: simplified transcription map of B19V genome. Five classes of mRNAs (mRNA 1-5) include 
a total of 12 different mRNAs species, arising from alternative usage of splicing and cleavage 
signals, as indicated by dashed lines, with different coding capacity for the main B19V proteins. 
 
Figure 2. 
Analytical profile of a group of serum samples sent to the diagnostic virology laboratory of 
S.Orsola-Malpighi Hospital, University of Bologna, for a diagnosis of B19V infection. Samples were 
concurrently tested for the detection of B19V specific IgG and IgM antibodies by a VLP-based 
CLIA assay (Liaison XL, DiaSorin, Italy), and by qPCR for the detection of B19V DNA and 
determination of viral load [78]. Out of 293 samples, 53 (18%) resulted positive for the presence of 
B19V DNA, confirming active infection. Of these, 36 had IgM values >1.0, and 29 IgM values >3.0. 
Viral load ranged from 101 IU/mL up to 1010 IU/mL (IU: NIBSC international units). The ample 
dynamic range of CLIA assay requires a careful consideration of cut-off values, especially when 
considering low-level IgM positive results. qPCR confirms its essential role to discriminate active 
infections in case of low-level IgM results and in the detection of chronic infections. 
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